Aurobindo shares plunge on US import alert
This article was originally published in Scrip
Executive Summary
Shares of Aurobindo Pharma were on a downward spiral on Indian bourses on 24 February over concerns that an import alert from the US FDA for products from one of its units could hurt the firm and trigger follow-on regulatory action in other markets.
You may also be interested in...
Aurobindo In Trouble Again With FDA, Gets Form 483 With 11 Observations
The US Food and Drug Administration has flagged more problems at Aurobindo, issuing another Form 483 to the company over one of its plants in southern India. This one, containing 11 observations, sharply faults quality controls.
India IPR Realities: Pharma, Legal Heads Discuss Winds Of Change, ‘Damocles Sword’
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.
India IPR Wheels Are Turning: Novartis, Bayer, Sun, Legal Heads Discuss Realities
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.